Tango Therapeutics Inc (TNGX)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Barbara L. Weber
Employees:
90
100 BINNEY ST, SUITE 700, CAMBRIDGE, MA, 02142
(857) 320-4900

Tango Therapeutics, Inc. discovers and develops drugs for the treatment of cancer. Lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. Company also develops Ubiquitin-specific protease 1 and Target 3 for STK11-mutant cancers.

Data derived from most recent annual or quarterly report
Market Cap 235.503 Million Shares Outstanding88.203 Million Avg 30-day Volume 188.675 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-1.26
Price to Revenue14.0086 Debt to Equity0.0 EBITDA-111.341 Million
Price to Book Value1.5329 Operating Margin-466.37449999999995 Enterprise Value14.727 Million
Current Ratio6.391 EPS Growth-0.34 Quick Ratio6.216
1 Yr BETA 1.6261 52-week High/Low 8.56 / 2.47 Profit Margin-446.2603
Operating Cash Flow Growth-51.2616 Altman Z-Score0.1487 Free Cash Flow to Firm -104.906 Million
Earnings Report2023-08-10
View SEC Filings from TNGX instead.

View recent insider trading info

Tango Therapeutics Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding TNGX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding TNGX

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-03-02 by CRYSTAL ADAM
  • 4: filed on 2023-03-02 by WEBER BARBARA
  • 4: filed on 2023-03-02 by BECKMAN DANIELLA
  • 4: filed on 2023-03-02 by BARRY DOUGLAS
  • 4: filed on 2023-03-02 by HUANG ALAN
  • 4: filed on 2022-12-05 by WEITZMAN AARON
  • 3: filed on 2022-12-05 by WEITZMAN AARON
  • 4: filed on 2022-06-28 by BORISY ALEXIS
  • 4: filed on 2022-06-28 by Davis Aaron I.
  • 4: filed on 2022-06-28 by PETERS MALTE

    • Events (8k)

  • 8-K: filed on 2023-05-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-27:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-02-28:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-10:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2022-05-11:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-28:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-11-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-08-13:
    Item 2.01: Completion of Acquisition or Disposition of Assets
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 4.01: Changes in Registrant's Certifying Accountant
    Item 5.01: Changes in Control of Registrant
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 5.05: Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics
    Item 5.06: Change in Shell Company Status
    Item 5.07: Submission of Matters to a Vote of Security Holders

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    BECKMAN DANIELLA CHIEF FINANCIAL OFFICER

    • Officer
    		 96,709 2023-03-01 1

    WEBER BARBARA CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 1,457,137 2023-03-01 1

    CRYSTAL ADAM SEE REMARKS

    • Officer
    		 81,250 2023-03-01 2

    HUANG ALAN CHIEF SCIENTIFIC OFFICER

    • Officer
    		 167,584 2023-03-01 1

    BARRY DOUGLAS GENERAL COUNSEL

    • Officer
    		 23,898 2023-03-01 1

    WEITZMAN AARON CHIEF MEDICAL OFFICER

    • Officer
    		 0 2022-12-01 2

    BOXER CAPITAL, LLC

    BOXER ASSET MANAGEMENT INC.

    LEWIS JOSEPH

    MVA INVESTORS, LLC

    DAVIS AARON I.

    • Director
    • 10% Owner
    		 7,392,166 2022-10-11 2

    BOXER CAPITAL, LLC

    BOXER ASSET MANAGEMENT INC.

    LEWIS JOSEPH

    • 10% Owner
    		 7,053,642 2022-10-04 2

    BORISY ALEXIS

    • Director
    		 40,000 2022-06-08 1

    DAVIS AARON I.

    • Director
    		 40,000 2022-06-08 1

    HUBER REID M

    • Director
    		 40,000 2022-06-08 1

    CALHOUN LESLEY ANN

    • Director
    		 40,000 2022-06-08 1

    ROTHENBERG MACE

    • Director
    		 40,000 2022-06-08 1

    PETERS MALTE

    • Director
    		 40,000 2022-06-08 1

    RUDOLTZ MARC CHIEF MEDICAL OFFICER

    • Officer
    		 350,000 2021-11-01 0

    BOXER CAPITAL, LLC

    BOXER ASSET MANAGEMENT INC.

    LEWIS JOSEPH

    MVA INVESTORS, LLC

    • 10% Owner
    		 6,973,166 2021-08-10 2

    BRASLYN LTD.

    LEWIS JOSEPH

    • 10% Owner
    		 26,961 2021-08-10 2

    THIRD ROCK VENTURES IV, L.P.

    THIRD ROCK VENTURES GP IV, L.P.

    TRV GP IV, LLC

    • 10% Owner
    		 19,363,975 2021-08-10 0

    BCTG HOLDINGS, LLC

    • 10% Owner
    		 6,988,450 2021-08-10 0

    AVERY JAMES B

    • Director
    		 0 2020-10-06 0

    FUGLESANG CHRISTOPHER PRESIDENT

    • Officer
    • Director
    		 0 2020-09-02 0

    BAUM CHARLES M

    • Director
    		 40,600 2020-09-02 0

    HEYMAN RICHARD A.

    • Director
    		 40,600 2020-09-02 0

    CHRISTENSEN JAMIE

    • Director
    		 40,600 2020-09-02 0

    NUECHTERLEIN CAROLE

    • Director
    		 0 2020-09-02 0

    ELLIS ANDREW RUEL COO AND SECRETARY

    • Officer
    		 0 2020-09-02 0

    BEAUCHAMP MICHAEL CFO AND TREASURER

    • Officer
    		 0 2020-09-02 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    TANGO THERAPEUTICS INC TNGX 2023-06-02 22:15:04 UTC 4.0457 1.0143 200000
    TANGO THERAPEUTICS INC TNGX 2023-06-02 21:45:04 UTC 4.0457 1.0143 200000
    TANGO THERAPEUTICS INC TNGX 2023-06-02 21:15:04 UTC 4.0457 1.0143 200000
    TANGO THERAPEUTICS INC TNGX 2023-06-02 20:45:03 UTC 4.0457 1.0143 200000
    TANGO THERAPEUTICS INC TNGX 2023-06-02 20:15:05 UTC 4.0457 1.0143 200000
    TANGO THERAPEUTICS INC TNGX 2023-06-02 19:45:04 UTC 4.0457 1.0143 200000
    TANGO THERAPEUTICS INC TNGX 2023-06-02 19:15:04 UTC 4.0457 1.0143 200000
    TANGO THERAPEUTICS INC TNGX 2023-06-02 18:45:04 UTC 4.0457 1.0143 200000
    TANGO THERAPEUTICS INC TNGX 2023-06-02 18:15:04 UTC 4.0457 1.0143 200000
    TANGO THERAPEUTICS INC TNGX 2023-06-02 17:45:03 UTC 4.0457 1.0143 200000
    TANGO THERAPEUTICS INC TNGX 2023-06-02 17:15:04 UTC 4.0457 1.0143 200000
    TANGO THERAPEUTICS INC TNGX 2023-06-02 16:45:03 UTC 4.0832 0.9868 200000
    TANGO THERAPEUTICS INC TNGX 2023-06-02 16:15:04 UTC 4.0832 0.9868 250000
    TANGO THERAPEUTICS INC TNGX 2023-06-02 15:45:04 UTC 4.0832 0.9868 250000
    TANGO THERAPEUTICS INC TNGX 2023-06-02 15:15:03 UTC 4.0832 0.9868 250000
    TANGO THERAPEUTICS INC TNGX 2023-06-02 14:45:04 UTC 4.0832 0.9868 250000
    TANGO THERAPEUTICS INC TNGX 2023-06-02 14:15:03 UTC 4.0832 0.9868 250000
    TANGO THERAPEUTICS INC TNGX 2023-06-02 13:45:03 UTC 3.9115 1.1585 250000
    TANGO THERAPEUTICS INC TNGX 2023-06-02 13:15:04 UTC 3.9115 1.1585 250000
    TANGO THERAPEUTICS INC TNGX 2023-06-02 12:45:03 UTC 3.9115 1.1585 250000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund TNGX -1200.0 shares, $-4740.0 2023-03-31 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments